secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0001842952-24-000050
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics acquires CT-95 (mesothelin x CD3 T cell engager) for $3.75M
--------------------------------------------------------------------------------

- Acquired CT-95 from Link (assignment for benefit of creditors) for $3.75M upfront payment.
- CT-95 is IND-cleared; Phase 1 trial expected to initiate in Q1 2025.
- Targets mesothelin, prevalent in ovarian, lung, and pancreatic cancers.
- Advancement through Phase 1 dose escalation to be funded with existing cash.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000050/0001842952-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295224000050/cntx-20240709.htm
  HTML page:      https://secwatch.observer/filing/0001842952-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer